

## BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26

HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 19, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the financial results and answer questions.

### **Conference Call & Webcast**

**Thursday, March 26, 2015 at 8:30 a.m. EDT/5:30 a.m. PDT**

Domestic: 888-510-1786

International: 719-325-2484

Conference

ID: 7135580

Webcast: <http://public.viavid.com/player/index.php?id=113504>

### **Replay – Available through April 9, 2015**

Domestic: 877-870-5176

Israel: 809-245-906

International: 858-384-5517

Conference

ID: 7135580

### **About BrainStorm Cell Therapeutics Inc.**

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ has been administered to approximately 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at [www.brainstorm-cell.com](http://www.brainstorm-cell.com).

### **Safe Harbor Statement**


Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Logo - <http://photos.prnewswire.com/prnh/20141006/150511>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-report-fourth-quarter-and-full-year-2014-financial-results-on-thursday-march-26-300053345.html>

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media: Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460, [info@brainstorm-cell.com](mailto:info@brainstorm-cell.com) or Investors: Michael Wood, LifeSci Advisors, LLC, 646-597-6983, [mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)

Additional assets available online:  [Photos \(1\)](#)

<https://ir.brainstorm-cell.com/2015-03-19-BrainStorm-Cell-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2014-Financial-Results-on-Thursday-March-26>